NA71
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
08/09/2025
Back to search
Official data from USPTO
EMPRISE EMPAGLIFLOZIN REAL-WORLD EFFECTIVENESS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
31
Latest update
08/10/2025
Trademark type
Combined
Nice classes
42
Filing date
09/28/2018
Registration date
07/02/2019
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
08/09/2025
Last transaction
08/10/2025
Responsible office
United States Patent and Trademark Office
Status code
706
Official register
Principal Register
Drawing code
3
Owner type
27
Owner location
DE
Examiner
EISNACH, MICHAEL
Current location
Historical data usage
Mark description
The mark consists of the wording "EMPRISE" in black font. Below this is the wording "EMPAGLIFLOZIN REAL-WORLD EFFECTIVENESS" in blue. To the right of the wording is a red heart with magnifying glass covering the upper right portion of the heart. The magnifying glass is white and the lens of the magnifying glass is purple. Inside the lens is a stylized outline of a globe that transitions from white to purple from right to left. The color white appearing elsewhere in the mark is for background purposes only and is not claimed as a feature of the mark.
Holders and representatives
Holders
Boehringer Ingelheim International GmbH
Representatives
Max Moskowitz Ostrolenk Faber LLP
Technical classification
Nice Classes
Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 42
Medical and scientific research in the field of diabetescardiovascular diseases and chronic kidney disease; Providing medical and scientific research information in the field of diabetescardiovascular diseases and chronic kidney disease
Publications
History of USPTO decisions and trademark events.
31 publications found
71AG
REGISTERED-SEC.71 ACCEPTED
08/09/2025
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
07/28/2025
ES71
TEAS SECTION 71 RECEIVED
04/22/2025
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
07/02/2024
FINV
FINAL DECISION TRANSACTION PROCESSED BY IB
12/01/2019
XXSS
GENERIC MADRID TRANSACTION SENT TO IB
10/23/2019
XXCR
GENERIC MADRID TRANSACTION CREATED
10/23/2019
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
10/02/2019
R.PR
REGISTERED-PRINCIPAL REGISTER
07/02/2019
CORN
CORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED
05/06/2019
CRCV
CORRECTION TRANSACTION RECEIVED FROM IB
04/19/2019
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
04/16/2019
PUBO
PUBLISHED FOR OPPOSITION
04/16/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
03/27/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/09/2019
CNEA
EXAMINERS AMENDMENT MAILED
03/08/2019
XAEC
EXAMINER'S AMENDMENT ENTERED
03/08/2019
CNEA
EXAMINERS AMENDMENT -WRITTEN
03/08/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/07/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/07/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/07/2019
RFNT
REFUSAL PROCESSED BY IB
02/22/2019
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
02/06/2019
RFRR
REFUSAL PROCESSED BY MPU
02/06/2019
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
01/24/2019
CNRT
NON-FINAL ACTION WRITTEN
01/23/2019
MAFR
APPLICATION FILING RECEIPT MAILED
01/22/2019
DOCK
ASSIGNED TO EXAMINER
01/16/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/16/2019
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
01/10/2019
Continuous trademark protection
Get notified about every new filing that threatens EMPRISE EMPAGLIFLOZIN REAL-WORLD EFFECTIVENESS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.